AI in Health Care: Balancing Benefits and Barriers
AI can help alleviate the burden on clinical labs—but only with sufficient investment, enthusiasm, and understanding
Clinical Diagnostics Insider
(formerly Diagnostic Testing and Emerging Technologies)
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
Esophageal Pre-Cancer Testing Gaining Greater Traction
How three companies are addressing screening challenges with tests that help improve chances of early detection
Computing the Future of the Lab
Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab
Dissecting the Data Behind Healthcare AI
How do the underlying datasets affect artificial intelligence tools’ performance in the lab—and beyond?
Has Your AI Been Validated?
Many artificial intelligence-based medical devices have not undergone clinical validation—but what does this mean for the lab?
‘Full Speed Ahead’ with Test Results? Not So Fast
Lab scientists using testing equipment too quickly brings up training concerns in discussions at recent ADLM conference
Diagnostics Pipeline: Recent FDA Approvals Aim to Make HPV Testing for Women More Accessible
Expansion of use for two assays gives patients the option to self-collect specimens at home and in the clinic, which may help address gaps in screening
Removing Restrictions to Germline Testing
With the global cancer burden growing, is a universal germline genomic testing approach the key to more effectively combating the disease?
PGx Testing: First, Do No Harm
Recent advances in pharmacogenomic testing—and their role in ensuring safe, effective treatment selection for precision oncology
The Demand for Digital Pathology
When it comes to cancer, patients’ greatest fear is diagnostic delays—and they believe digital pathology and AI can reduce those delays
Diagnostics Pipeline: Scientists Ask Agency to Rescind Approval for Opioid Management Test
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’
Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
Advances in Point of Care Tech Alter the Genetic Testing Landscape
How are advances in point-of-care testing altering the genetic testing landscape, and what does this mean for the clinical lab?
